Physician profile
Steven Konicki
NPI 1164512034
$2,073.64
in general payments reported to CMS, 2019-2025
17 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $88.76 · 2022: $144 · 2023: $626 · 2024: $930 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $793.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $200.67 | 2022-2025 | |
| Abbott Laboratories | $196.86 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.49 | 2023-2024 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $109.13 | 2023-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Pfizer INC. | $102.42 | 2023-2024 | |
| Lilly USA, LLC | $101.27 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $68.08 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $67.71 | 2022-2024 | |
| Glaxosmithkline, LLC. | $58.61 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $45.71 | 2023-2025 | Farxiga |
| Horizon Therapeutics Plc | $35.81 | 2023 | Krystexxa |
| Amgen INC. | $33.19 | 2024 | Repatha, Otezla |
| Alkermes, INC. | $27.79 | 2023 | Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $25.45 | 2025 | Eliquis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.42 | 2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $24.03 | 2023 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Konicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.